Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.
Miranda Hughes, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.
Terracciano L, Glatz K, Mhawech P et al.. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases. Am J Surg Pathol 2003;27:1302–1312.
Ishikura H, Kanda M, Ito M et al.. Hepatoid adenocarcinoma: a distinctive histological subtype of alpha-fetoprotein-producing lung carcinoma. Virchows Arch A Pathol Anat Histopathol 1990;417:73–80.
Mokrim M, Belbaraka R, Allaoui M et al.. Hepatoid adenocarcinoma of the lung: a case report and literature review. J Gastrointest Cancer 2012;43(Suppl 1):125–127.
Lin SF, Hsu WH, Chou TY. Primary pulmonary hepatoid carcinoma: report of a case and review of the literature. Kaohsiung J Med Sci 2013;29:512–516.
Haninger D, Kloecker G, Bousamra M et al.. Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature. Modern Pathol 2014;27:535–542.
Lei JY, Bourne P, diSant’Agnese PA, Huang J. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol 2006;125:519–525.
Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
Paz-Ares LG, Biesma B, Heigener D et al.. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012;30:3084–3092.
Scagliotti G, Novello S, von Pawel J et al.. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835–1842.
Blumenschein GR Jr, Saintigny P, Liu S et al.. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 2013;19:6967–6975.
Metro G, Minotti V, Crino L. Years of sorafenib investigation in advanced non-small cell lung cancer: is there a ‘NExUS’ linking an unsuccessful treatment and a potential active one? J Thorac Dis 2012;4:635–638.
Carlinfante G, Foschini MP, Pasquinelli G et al.. Hepatoid carcinoma of the lung: a case report with immunohistochemical, ultrastructural and in-situ hybridization findings. Histopathology 2000;37:88–89.
Nasu M, Soma T, Fukushima H et al.. Hepatoid carcinoma of the lung with production of alpha-fetoprotein and abnormal prothrombin: an autopsy case report. Mod Pathol 1997;10:1054–1058.
Hiroshima K, Iyoda A, Toyozaki T et al.. Alpha-fetoprotein-producing lung carcinoma: report of three cases. Pathol Int 2002;52:46–53.
Kishimoto T, Yano T, Hiroshima K et al.. A case of alpha-fetoprotein-producing pulmonary carcinoma with restricted expression of hepatocyte nuclear factor-4 alpha in hepatoid foci: a case report with studies of previous cases. Hum Pathol 2008;39:1115–1120.
Arnold L, Drout F, Fargeot P et al.. Hepatoid adenocarcinoma of the lung: report of a case of an unusual alfa-fetoprotein-producing lung tumor. Am J Surg Pathol 1997;21:1113–1118.
Wu Z, Upadhyaya M, Zhu H et al.. Hepatoid adenocarcinoma: computed tomographic imaging findings with histopathologic correlation in 6 cases. J Comput Assist Tomogr 2007;31:846–852.